当前位置:科学网首页 > 小柯机器人 >详情
DNA断裂处变构PARP-1滞留的结构基础获解析
作者:小柯机器人 发布时间:2020/4/5 21:18:02

美国宾夕法尼亚大学Ben E. Black、加拿大蒙特利尔大学John M. Pascal等研究人员合作解析了DNA断裂处变构PARP-1滞留的结构基础。这一研究成果于2020年4月3日发表在《科学》杂志上。

研究人员表示,聚(ADP-核糖)聚合酶-1(PARP-1)抑制剂(PARPi)能否成功治疗癌症,与它们在DNA断裂位点抑制PARP-1的能力有关。尽管不同形式的PARPi都靶向酶的催化中心,但是它们具有可变的PARP-1抑制能力。
 
研究人员发现,几个结构独特的PARPi引起PARP-1变构,从而促进DNA断裂的释放。其他抑制剂会导致变构物在DNA断裂时保留PARP-1。此外,他们研发了新的PARPi化合物,将变构的促释化合物转变为促留化合物,并提高了其杀死癌细胞的能力。无论PARP-1抑制是否需要,这些研发都与临床应用有关。
 
附:英文原文

Title: Structural basis for allosteric PARP-1 retention on DNA breaks

Author: Levani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, Mark A. Hancock, Jamin D. Steffen, Ramya Billur, Zain M. Hannan, Andrew J. Wicks, Dragomir B. Krastev, Stephen J. Pettitt, Christopher J. Lord, Tanaji T. Talele, John M. Pascal, Ben E. Black

Issue&Volume: 2020/04/03

Abstract: Abstract

The success of poly(ADP-ribose) polymerase–1 (PARP-1) inhibitors (PARPi) to treat cancer relates to their ability to trap PARP-1 at the site of a DNA break. Although different forms of PARPi all target the catalytic center of the enzyme, they have variable abilities to trap PARP-1. We found that several structurally distinct PARPi drive PARP-1 allostery to promote release from a DNA break. Other inhibitors drive allostery to retain PARP-1 on a DNA break. Further, we generated a new PARPi compound, converting an allosteric pro-release compound to a pro-retention compound and increasing its ability to kill cancer cells. These developments are pertinent to clinical applications where PARP-1 trapping is either desirable or undesirable.

DOI: 10.1126/science.aax6367

Source: https://science.sciencemag.org/content/368/6486/eaax6367

期刊信息
Science:《科学》,创刊于1880年。隶属于美国科学促进会,最新IF:41.037